AVELOS THERAPEUTICS Trademark

Trademark Overview


On Wednesday, June 1, 2022, a trademark application was filed for AVELOS THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the AVELOS THERAPEUTICS trademark a serial number of 97439188. The federal status of this trademark filing is SUSPENSION INQUIRY - MAILED as of Wednesday, December 20, 2023. This trademark is owned by Avelos Therapeutics, Inc.. The AVELOS THERAPEUTICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations and substances, for use in the field of oncology, central nervous system, immunology, and metabolic disease, namely for the prevention and treatment of diseases of the central nervous system, immunological diseases, and metabolic diseases for medical purposes; anti-cancer preparations; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations for the treatment of cancer; biopharmaceuticals, namely, pharmaceutical products for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; compounds, namely, chemical preparations for treating cancer; biological preparations for the treatment of cancer; diagnostic preparations for medical purposes; biological preparations for the treatment of cancer for medical purposes

Scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; consultancy relating to scientific research in the field of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; pharmaceutical research services; research and development of technology in the field of biotechnology; pharmaceutical research of biologics
avelos therapeutics

General Information


Serial Number97439188
Word MarkAVELOS THERAPEUTICS
Filing DateWednesday, June 1, 2022
Status651 - SUSPENSION INQUIRY - MAILED
Status DateWednesday, December 20, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances, for use in the field of oncology, central nervous system, immunology, and metabolic disease, namely for the prevention and treatment of diseases of the central nervous system, immunological diseases, and metabolic diseases for medical purposes; anti-cancer preparations; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations for the treatment of cancer; biopharmaceuticals, namely, pharmaceutical products for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; compounds, namely, chemical preparations for treating cancer; biological preparations for the treatment of cancer; diagnostic preparations for medical purposes; biological preparations for the treatment of cancer for medical purposes
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesScientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; consultancy relating to scientific research in the field of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; pharmaceutical research services; research and development of technology in the field of biotechnology; pharmaceutical research of biologics

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 9, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 9, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAvelos Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGangseo-gu, Seoul 07794
KR

Trademark Events


Event DateEvent Description
Saturday, June 4, 2022NEW APPLICATION ENTERED
Thursday, June 9, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 17, 2023ASSIGNED TO EXAMINER
Monday, March 20, 2023NON-FINAL ACTION WRITTEN
Monday, March 20, 2023NON-FINAL ACTION E-MAILED
Monday, March 20, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 20, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 20, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 21, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 22, 2023SUSPENSION LETTER WRITTEN
Thursday, June 22, 2023LETTER OF SUSPENSION E-MAILED
Thursday, June 22, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, December 20, 2023SUSPENSION INQUIRY WRITTEN
Wednesday, December 20, 2023INQUIRY TO SUSPENSION E-MAILED
Wednesday, December 20, 2023NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Friday, March 15, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, March 15, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, June 20, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED